DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Anticholinesterase agents (Cont.):
secretory glands and, 246
structure-activity relationships,
242–245
therapeutic uses of, 250–253
toxicology of, 247–250
treatment of intoxication by,
248–249
Anticholinesterase poisoning, 234
Anticoagulants, 849
antithrombin (recombinant), 860
argatroban, 860
bivalirudin, 859–860
clinical use and monitoring of, 865
desirudin, 859
drotrecogin alfa, 860
oral
decreased effect of, causes,
863–864
drug interactions with, 863–864
mechanism of action of, 860–862
new, 865–866
parenteral, 853–860
Anticonvulsants, for mania, 444–445
Antidepressants, 398–413
adverse effects of, 410–413
amine effects of, 400t–403t
atypical, disposition of, 409t
clinical considerations with, 399,
405
disposition of, 409t
dosage of, 400t–403t
drug interactions with, 412
mechanism of action of, 398–399
norepinephrine-selective, potencies,
at human transporters for
monamine neurotransmitters,
406t
polymorphisms and response to,
159t, 160t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
serotonin-selective, potencies, at
human transporters for
monamine neurotransmitters,
406t
side effects of, 400t–403t
ultra-rapid pharmacokinetics of, 157
Antidiuretic hormone (ADH), opioids
and, 495
Antidiuretic system, mammalian,
anatomy of, 701–702
Antidotal therapies, 85, 86t
Antiemetic agents, 1341–1346
arrhythmias caused by, 832
in cancer chemotherapy, 1344t
in combination, 1344t
Anti-emetics, antipsychotics as, 436
Antiepileptic drugs
barbiturates, 593–594
benzodiazepines, 598–599
choice of, 603–606
duration of therapy with, 604–605
general principles, 603–606
history of, 590
hydantoins, 591–593
iminostilbenes, 594–596
pregnancy and, 605–606
succinimides, 596
therapeutic aspects of, 590
valproic acid, 596–598
Antiestrogens, 1668t–1670t
Anti-estrogens, pure, 1177–1180,
1756, 1759–1760
Anti-estrogen therapy, 1756–1760
for ER+ breast cancer, 1756–1760,
1757t
Antiflatulence agents, 1347
Antifungal agents
ABC transporters and, 105t
amphotericin B, 1571–1575
arrhythmias caused by, 832
cutaneous, 1816t
flucytosine, 1575–1576
imidazoles, 1576
itraconazole, 1576–1579
ketoconazole, 1576
oral, 1816t
for skin disease, 1817–1818
and statins, interactions, 896
systemic, 1571–1586
topical, 1586–1589, 1816t
triazoles, 1576
Antigenic complex, 76
Antigens, immunological tolerance
and, 1021
Antiglucocorticoids, 1236
Anti-hepatitis agents, 1609–1617
Antiherpesvirus agents, 1593–1605,
1596t
Antihistamines, 911
anti-pruritic effects, 1815–1816
arrhythmias caused by, 832
clinical summary, 925–926
for nausea and vomiting, 1344
nonsedating, 911, 920
pharmacokinetics of, 1816t
Antihistamines (Cont.):
for pruritus, 1815–1816, 1828t
third generation, 911
Antihypertensive agents, 774t. See also
Hypertension; specific agent
ACE inhibitors, 734
angiotensin II receptor antagonists,
738–745
direct renin inhibitors, 745–747
Anti-IgE receptor therapy, 1054
Anti-inflammatory agents, in
dermatology, 1822–1824
Anti-influenza agents, 1596t,
1605–1609
Anti-integrin agents, for myocardial
ischemia, 771
ANTILIRIUM (physostigmine salicylate),
250
Antimalarial agents, 1386t–1395t
artemisinin and derivatives, 1386,
1395–1398
classification of, 1389–1390
in dermatology, 1819
mechanism of action of, 1819
pharmacogenetics in, 154
Antimetabolites, 1668t–1670t
in dermatology, 1820–1821
for neoplastic disease, 1668t–1670t
Antimicrobial agents. See also
Antibiotic(s)
actions of, 1365
classes of, 1365
for cutaneous infections, 1816–1819
dosage of, 1371–1373
evolutionary basis of resistance to,
1377–1378
goals of therapy with, 1373–1375
penetration into anatomic
compartments, 1366–1367
pharmacokinetics compartments,
1367–1368
pharmacokinetics of, 1366–1369
population pharmacokinetics,
1368–1369
pre-emptive, 1374–1375
prophylactic use of, 1373–1375
resistance mechanisms, 1375–1377
response variability, 1368–1369
scientific basis of, 1365
susceptibility testing and, 1369–
1371
types of therapy with, 1373–1375
Antimycobacterial drugs, 1549–1564
Antinausea agents, 1341–1346
Antineoplastic agents, 1668t–1670t
1999
INDEX